Why I think Greencross Limited looks a buy at this share price

The Greencross Limited (ASX:GXL) share price is up almost 10% since its interim results announcement.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Veterinary services and pet care retailer Greencross Limited (ASX: GXL) announced a pleasing set of half-year results last Tuesday; revenue was up, profit was up, but more importantly, the company was able to achieve solid like-for-like sales growth for the first half of FY2017.

This measurement of same-stores performance is important when assessing expanding retailers like Greencross, and it appears the company's plan for growth is working.

Greencross is the largest integrated pet care company in Australia, with 124 veterinary clinics and 200 stores through its City Farmers and Pet Barn retail brands. It also operates clinics in New Zealand and has a 50% stake in the Animates retailer there. The company listed in 2007 with ambitious plans for expansion and isn't about to stop now.

After adding 16 retail stores and 10 clinics in the first half of FY2017, Greencross is aiming to add 20 stores a year towards its long-term goal of 350 stores across Australia and New Zealand. That's more than 100 stores to reach its current target. This growth story is far from over.

What separates Greencross from other pet care retailers and veterinary service providers is that it can offer both under the one roof. The company currently has 25 clinics operating inside its retail establishments and believes the current network alone will support 120. Furthermore, all future stores will include a clinic where practical.

There are a number of benefits from having vet clinics situated within the retail store. Firstly, Greencross has found that retail spending is higher and the frequency of customer visits is higher for cross-shopping at in-store clinics. Capital expenditure costs to set up an in-store clinic are around half, versus an acquisition.

Then there's also the ongoing savings from maintaining fewer properties. Greencross management has observed what counterpart Pets At Home has achieved with a similar model in the UK and aims to replicate that success here.

Further growth opportunities for Greencross include its new private label pet food, in-store grooming services, online retail sales and their preventative healthcare program for dogs and cats, Healthy Pets Plus.

If you're not convinced of the feasibility of Greencross' expansion, consider this: according to a pet ownership study conducted by Animal Medicines Australia, Australians spent an estimated $11b on their dogs and cats in 2016. That would put Greencross's current market share at less than 10%. Plenty of room to grow in what is a fragmented industry.

Often a key risk for expanding retailers is the increasing debt incurred when acquiring and creating new stores. What impressed me from Greencross's recent result is that despite its growth it was actually able to reduce net debt over the period. The latest dividend will represent a payout ratio around 50%, allowing the company to effectively use earnings to sustain growth and manage debt.

Foolish takeaway

Famous fund manager Peter Lynch liked to invest in companies that were easy to understand. A famous mantra of his is "invest in what you know". Some of his most successful investments were retailers that expanded nationally, with increasing like-for-like sales, serviceable debt, and management that followed their expansion plans as outlined to shareholders. For me, Greencross ticks those same boxes and I intend to be a shareholder for the long term.

Motley Fool contributor Ian Crane owns shares of Greencross Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »